InvestorsHub Logo
Followers 2
Posts 188
Boards Moderated 0
Alias Born 01/09/2019

Re: None

Sunday, 01/22/2023 1:58:36 PM

Sunday, January 22, 2023 1:58:36 PM

Post# of 575
Mutations that have yielded a CR with TUSP: FLT3; IDH2; SRSF2; TP53; NPM1; DNMT3a; RUNX1; NRAS; SF3B1; RB1; MLL-PTD; BCOR; U2AF1; SETBP1
Mutations that have yielded a PR with TUSP: KRAS; IDH1; PTPN11; ASXL1; CBL
Preclinical Cell line data suggests the LUX is effective against mutant NRAS; IDH1; SRF2 and ASXL1.
Preclinical Cell line data suggests the LUX is effective against several mutants that are also hit by TUSP leading to potential additive or synergistic effects.
Both TUSP and LUX have very favorable safety profiles and both are synergistically enhanced by venetoclax. They have been combined in vitro (data not shown-yet).
Primary emergent resistance mutants to Gilteritinib are NRAS; KRAS; TP53.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent APTO News